S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Disney Stock Catches 3 Upgrades In a Single Week
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages

Kiniksa Pharmaceuticals (KNSA) Stock Price, News & Analysis

$19.73
-0.26 (-1.30%)
(As of 03/28/2024 ET)
Today's Range
$19.47
$20.13
50-Day Range
$17.63
$21.74
52-Week Range
$10.29
$22.09
Volume
359,719 shs
Average Volume
436,383 shs
Market Capitalization
$1.39 billion
P/E Ratio
109.62
Dividend Yield
N/A
Price Target
$28.00

Kiniksa Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
41.9% Upside
$28.00 Price Target
Short Interest
Bearish
4.06% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$1.27 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.05) to ($0.43) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.30 out of 5 stars

Medical Sector

359th out of 939 stocks

Pharmaceutical Preparations Industry

171st out of 444 stocks

KNSA stock logo

About Kiniksa Pharmaceuticals Stock (NASDAQ:KNSA)

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

KNSA Stock Price History

KNSA Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Kiniksa Pharmaceuticals Ltd.
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
What Wall Street expects from Kiniksa Pharmaceuticals's earnings
GSK (GSK) Misses Q4 Earnings Estimates
See More Headlines
Receive KNSA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kiniksa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
3/29/2024
Next Earnings (Estimated)
5/07/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KNSA
Fax
N/A
Employees
297
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$28.00
High Stock Price Target
$28.00
Low Stock Price Target
$28.00
Potential Upside/Downside
+41.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$14.08 million
Pretax Margin
-6.16%

Debt

Sales & Book Value

Annual Sales
$270.26 million
Book Value
$6.23 per share

Miscellaneous

Free Float
32,320,000
Market Cap
$1.39 billion
Optionable
Optionable
Beta
0.28
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Sanj K. Patel (Age 55)
    CEO & Chairman of the Board
    Comp: $1.44M
  • Mr. Eben Tessari (Age 42)
    Senior VP & COO
    Comp: $643.75k
  • Dr. John F. Paolini (Age 59)
    Senior VP & Chief Medical Officer
    Comp: $753.7k
  • Mr. Mark Ragosa C.F.A. (Age 50)
    Senior VP & CFO
  • Mr. Michael R. Megna CPA (Age 53)
    Chief Accounting Officer & Group VP of Finance
  • Ms. Mei Jang
    Senior VP of Technical Operations
  • Rachel Frank
    Associate Director of Investor Relations
  • Mr. Chad Morin
    SVP, Chief Compliance Officer & Head of Quality
  • Ms. Madelyn Demsky Zeylikman (Age 50)
    SVP, General Counsel & Secretary
  • Ms. Melissa Manno
    Senior VP & Chief Human Resources Officer

KNSA Stock Analysis - Frequently Asked Questions

Should I buy or sell Kiniksa Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" KNSA shares.
View KNSA analyst ratings
or view top-rated stocks.

What is Kiniksa Pharmaceuticals' stock price target for 2024?

1 equities research analysts have issued 12-month target prices for Kiniksa Pharmaceuticals' shares. Their KNSA share price targets range from $28.00 to $28.00. On average, they expect the company's share price to reach $28.00 in the next twelve months. This suggests a possible upside of 41.9% from the stock's current price.
View analysts price targets for KNSA
or view top-rated stocks among Wall Street analysts.

How have KNSA shares performed in 2024?

Kiniksa Pharmaceuticals' stock was trading at $17.54 at the beginning of 2024. Since then, KNSA stock has increased by 12.5% and is now trading at $19.73.
View the best growth stocks for 2024 here
.

When is Kiniksa Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024.
View our KNSA earnings forecast
.

How were Kiniksa Pharmaceuticals' earnings last quarter?

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) announced its quarterly earnings results on Wednesday, February, 28th. The company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.15. The firm earned $83.40 million during the quarter, compared to the consensus estimate of $72.31 million. Kiniksa Pharmaceuticals had a net margin of 5.11% and a negative trailing twelve-month return on equity of 6.12%.

What ETFs hold Kiniksa Pharmaceuticals' stock?

ETFs with the largest weight of Kiniksa Pharmaceuticals (NASDAQ:KNSA) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP).ALPS Medical Breakthroughs ETF (SBIO).

What is Sanj K. Patel's approval rating as Kiniksa Pharmaceuticals' CEO?

1 employees have rated Kiniksa Pharmaceuticals Chief Executive Officer Sanj K. Patel on Glassdoor.com. Sanj K. Patel has an approval rating of 100% among the company's employees. This puts Sanj K. Patel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Kiniksa Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kiniksa Pharmaceuticals investors own include Exelixis (EXEL), CRISPR Therapeutics (CRSP), Pfizer (PFE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Dicerna Pharmaceuticals (DRNA), Vaxart (VXRT) and Advanced Micro Devices (AMD).

When did Kiniksa Pharmaceuticals IPO?

Kiniksa Pharmaceuticals (KNSA) raised $126 million in an IPO on Thursday, May 24th 2018. The company issued 7,000,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Who are Kiniksa Pharmaceuticals' major shareholders?

Kiniksa Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.22%), Vanguard Group Inc. (4.20%), Rubric Capital Management LP (4.13%), Goldman Sachs Group Inc. (1.29%), Goldman Sachs Group Inc. (1.29%) and Granahan Investment Management LLC (1.03%). Insiders that own company stock include Barry D Quart, John F Paolini, Mark Ragosa, Michael R Megna and Sanj K Patel.
View institutional ownership trends
.

How do I buy shares of Kiniksa Pharmaceuticals?

Shares of KNSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KNSA) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners